Actively Recruiting

Phase 2
Age: 18Years - 25Years
All Genders
NCT06569394

A Study of Cannabidiol in Young Adult Cannabis Users

Led by University of Colorado, Denver · Updated on 2026-05-01

200

Participants Needed

1

Research Sites

185 weeks

Total Duration

On this page

Sponsors

U

University of Colorado, Denver

Lead Sponsor

N

National Institute on Drug Abuse (NIDA)

Collaborating Sponsor

AI-Summary

What this Trial Is About

The investigators will study the harm-reducing effect of hemp-derived CBD in non-treatment-seeking emerging adults who use cannabis regularly. The study will use a novel naturalistic cannabis administration approach, which examines ecologically valid cannabis use utilizing a mobile lab setting to assess the effects of the cannabis products the participants regularly use. The investigators will recruit a sample of emerging adults, half of whom primarily use flower products and half of whom primarily use concentrate products. Individuals will be randomly assigned to hemp-derived CBD or placebo.

CONDITIONS

Official Title

A Study of Cannabidiol in Young Adult Cannabis Users

Who Can Participate

Age: 18Years - 25Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Ages 18 to 25 years
  • Use cannabis flower or concentrates at least five days per week for the past year
  • Not currently seeking to reduce or stop cannabis use
  • Have at least two symptoms of cannabis use disorder according to DSM-5
Not Eligible

You will not qualify if you...

  • Use of any illegal substances other than alcohol, nicotine, or cannabis in the past 60 days
  • Alcohol use on 3 or more days per week or more than 3 drinks per drinking day in the past 60 days
  • Daily use of nicotine
  • Diagnosis of psychotic disorder, bipolar disorder, major depression with suicidal ideation, or history of treatment for these
  • Current cardiovascular or respiratory diseases
  • Use of psychotropic or hepatotoxic medications
  • Use of anti-epileptic drugs or medications interacting with Epidiolex, or history of seizures
  • Use of strong or moderate CYP3A4 or CYP2C19 inhibitors or inducers
  • Current or past liver disease or abnormal liver function tests
  • For females, pregnancy, lactation, or not using approved birth control if of childbearing potential
  • Current suicidality risk determined by clinical assessment

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of Colorado Anschutz Medical Campus

Aurora, Colorado, United States, 80045

Actively Recruiting

Loading map...

Research Team

C

Christian J Hopfer, MD

CONTACT

K

Kristen M Raymond, BA

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here